{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04722887",
            "orgStudyIdInfo": {
                "id": "GC2008"
            },
            "organization": {
                "fullName": "Grifols Therapeutics LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency",
            "officialTitle": "A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin Deficiency",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-safety-tolerability-and-pharmacokinetics-of-two-different-doses-of-proteinase-inhibitor-subcutaneous-human-in-participants-with-antitrypsin-deficiency"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-14",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03-14",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-01-20",
            "studyFirstSubmitQcDate": "2021-01-20",
            "studyFirstPostDateStruct": {
                "date": "2021-01-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Grifols Therapeutics LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD)."
        },
        "conditionsModule": {
            "conditions": [
                "Alpha1-Antitrypsin Deficiency"
            ],
            "keywords": [
                "Pulmonary Emphysema",
                "Alpha-1 Antitrypsin Deficiency",
                "AATD",
                "Alpha-1 PI Deficiency",
                "Alpha-1 Proteinase Inhibitor",
                "Emphysema",
                "Pathologic Processes",
                "Pulmonary Disease, Chronic Obstructive",
                "Lung Diseases, Obstructive",
                "Lung Diseases",
                "Respiratory Tract Diseases",
                "Liver Diseases",
                "Digestive System Diseases",
                "Genetic Diseases, Inborn",
                "Subcutaneous Emphysema",
                "Alpha1-Antitrypsin",
                "Trypsin Inhibitors",
                "Serine Proteinase Inhibitors",
                "Protease Inhibitors",
                "Enzyme Inhibition",
                "Molecular Mechanisms of Pharmacological Action"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 16,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Alpha-1 15% 72 mg/kg, single weekly subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.",
                    "interventionNames": [
                        "Biological: Alpha-1 15%"
                    ]
                },
                {
                    "label": "Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)",
                    "type": "EXPERIMENTAL",
                    "description": "Following treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation phase, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.",
                    "interventionNames": [
                        "Biological: Liquid Alpha1-Proteinase Inhibitor (Human)"
                    ]
                },
                {
                    "label": "Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)",
                    "type": "EXPERIMENTAL",
                    "description": "Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.",
                    "interventionNames": [
                        "Biological: Alpha-1 15%"
                    ]
                },
                {
                    "label": "Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Alpha-1 15% 180 mg/kg, single weekly SC infusion in treatment-period 1 (Single-Dose) at Week 1.",
                    "interventionNames": [
                        "Biological: Alpha-1 15%"
                    ]
                },
                {
                    "label": "Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)",
                    "type": "EXPERIMENTAL",
                    "description": "Following treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation phase. During the single-dose data evaluation phase, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.",
                    "interventionNames": [
                        "Biological: Liquid Alpha1-Proteinase Inhibitor (Human)"
                    ]
                },
                {
                    "label": "Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)",
                    "type": "EXPERIMENTAL",
                    "description": "Following treatment period 1 and single-dose data evaluation phase, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 180 mg/kg, for 8 weekly SC infusions.",
                    "interventionNames": [
                        "Biological: Alpha-1 15%"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Alpha-1 15%",
                    "description": "Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion",
                    "armGroupLabels": [
                        "Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)",
                        "Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)",
                        "Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg)",
                        "Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg)"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Liquid Alpha1-Proteinase Inhibitor (Human)",
                    "description": "Intravenous infusion",
                    "armGroupLabels": [
                        "Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)",
                        "Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)"
                    ],
                    "otherNames": [
                        "Prolastin\u00ae-C Liquid"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants With Adverse Events (AEs)",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Number of Participants With Suspected Adverse Drug Reactions (ADRs)",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Number of Participants With Infusion Site Reactions",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Number of Participants With Serious Adverse Events (SAEs)",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Number of Participants With AEs and SAEs Leading to Discontinuation",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Number of Participants With Clinically Significant Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1)",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Change from Baseline in Forced Vital Capacity (FVC)",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)",
                    "timeFrame": "Up to 668 days"
                },
                {
                    "measure": "Immunogenicity: Number of Participants With Alpha1-PI Antibodies",
                    "timeFrame": "Treatment Period 1- Single-Dose Week 1; Treatment Period 2- Repeat-Dose Weeks 1 and 9"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a diagnosis of congenital Alpha1-antitrypsin deficiency (AATD) with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or \"at-risk\" alleles (subjects with \"at-risk\" alleles must be individually evaluated for eligibility by the Medical Monitor).\n* Have a documented pre-Alpha1-Proteinase Inhibitor (PI) augmentation therapy serum alpha-1 antitrypsin (AAT) level \\<11 micrometer (\u03bcM) (80 milligrams per decilitre (mg/dL) if measured by radial immunodiffusion or 50 mg/dL if measured by nephelometry).\n* Subjects may be na\u00efve to Alpha1-PI augmentation therapy or may be currently receiving Alpha1-PI augmentation therapy or received Alpha1-PI augmentation therapy within the past. If the subject is currently receiving Alpha1-PI augmentation therapy of any kind, he/she must be willing to discontinue that treatment for at least 25 days prior to the Week 1 (Baseline) Visit and remain off any kind of Alpha1-PI treatment, other than the IPs for this study, while participating in the study.\n* At the Screening Visit, have a post-bronchodilator forced expiratory volume (FEV1) \u226530% and \\<80% of predicted and FEV1/forced vital capacity (FVC) \\<70% (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II or III).\n\nExclusion Criteria:\n\n* Have had a moderate or severe Chronic obstructive pulmonary disease (COPD) exacerbation during the 4 weeks before the Week 1 (Baseline) Visit.\n* Have history of lung or liver transplant.\n* Have any lung surgery during the past 2 years (excluding lung biopsy).\n* Have severe concomitant disease (example, congestive heart failure, clinically significant pulmonary fibrosis, malignant disease \\[except for skin cancers other than melanoma\\], history of acute hypersensitivity pneumonitis reaction, or current chronic hypersensitivity pneumonitis).\n* Females who are pregnant, breastfeeding or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (oral, injectable, or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study.\n* Have smoked during the past 6 months or a positive urine cotinine test at the Screening Visit that is due to smoking.\n* Participate in another Investigational product (IP) study within one month prior to the Week 1 (Baseline) Visit.\n* Have history of anaphylaxis or severe systemic response to any plasma-derived Alpha1-PI preparation or other blood product(s).\n* Use systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e., 10 mg every 2 days) within the 4 weeks prior to the Week 1 (Baseline) Visit. It is recommended to maintain the same dose throughout the study.\n* Use systemic or aerosolized antibiotics for a chronic COPD exacerbation within the 4 weeks prior to the Week 1 (Baseline) Visit.\n* Have known selective or severe Immunoglobulin A (IgA) deficiency.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Beatriz Garcia Castro",
                    "role": "CONTACT",
                    "phone": "+(34) 670923669",
                    "email": "beatriz.garcia@grifols.com"
                },
                {
                    "name": "Elsa Mondou",
                    "role": "CONTACT",
                    "phone": "+1 919 316 2079",
                    "email": "elsa.mondou@grifols.com"
                }
            ],
            "locations": [
                {
                    "facility": "Dignity Health-St. Joseph's Hospital & Medical Center",
                    "status": "RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85013",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Noor Elkurwi",
                            "role": "CONTACT",
                            "phone": "602-406-5853",
                            "email": "noor.elkurwi@commonspirit.org"
                        },
                        {
                            "name": "Rajat Walia, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "UCLA Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Se Yoon",
                            "role": "CONTACT",
                            "email": "SeYoon@mednet.ucla.edu"
                        },
                        {
                            "name": "Igor Barjaktarevic, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "George Washington University",
                    "status": "WITHDRAWN",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20037",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "University of Florida",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32610",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Allison Faunce",
                            "role": "CONTACT",
                            "email": "Allison.Faunce@medicine.ufl.edu"
                        },
                        {
                            "name": "Jorge Lascano, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                },
                {
                    "facility": "University of Miami",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Biondo",
                            "role": "CONTACT",
                            "phone": "847-541-0094",
                            "email": "jnb184@med.miami.edu"
                        },
                        {
                            "name": "Michael Campos, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Southeastern Research Center",
                    "status": "WITHDRAWN",
                    "city": "Winston-Salem",
                    "state": "North Carolina",
                    "zip": "27103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.09986,
                        "lon": -80.24422
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shauna Jo Hendershot",
                            "role": "CONTACT",
                            "email": "HENDERS@ccf.org"
                        },
                        {
                            "name": "Tejwani Vickram, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Medical University of South Carolina - Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gwen Hayden",
                            "role": "CONTACT",
                            "email": "blantonm@musc.edu"
                        },
                        {
                            "name": "Charlie Strange, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                },
                {
                    "facility": "Renovatio Clinical",
                    "status": "WITHDRAWN",
                    "city": "The Woodlands",
                    "state": "Texas",
                    "zip": "77380",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.15799,
                        "lon": -95.48938
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019896",
                    "term": "Alpha 1-Antitrypsin Deficiency"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000013352",
                    "term": "Subcutaneous Emphysema"
                },
                {
                    "id": "D000004646",
                    "term": "Emphysema"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7812",
                    "name": "Emphysema",
                    "relevance": "LOW"
                },
                {
                    "id": "M11170",
                    "name": "Lung Diseases, Obstructive",
                    "relevance": "LOW"
                },
                {
                    "id": "M23449",
                    "name": "Pulmonary Disease, Chronic Obstructive",
                    "relevance": "LOW"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21776",
                    "name": "Alpha 1-Antitrypsin Deficiency",
                    "asFound": "Alpha-1 Antitrypsin Deficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M14510",
                    "name": "Pulmonary Emphysema",
                    "relevance": "LOW"
                },
                {
                    "id": "M16142",
                    "name": "Subcutaneous Emphysema",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T297",
                    "name": "Alpha-1 Antitrypsin Deficiency",
                    "asFound": "Alpha-1 Antitrypsin Deficiency",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000000515",
                    "term": "Alpha 1-Antitrypsin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000014361",
                    "term": "Trypsin Inhibitors"
                },
                {
                    "id": "D000015842",
                    "term": "Serine Proteinase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "asFound": "Morphine sulfate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3856",
                    "name": "Alpha 1-Antitrypsin",
                    "asFound": "Legacy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20205",
                    "name": "Protein C Inhibitor",
                    "relevance": "LOW"
                },
                {
                    "id": "M17112",
                    "name": "Trypsin Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M18391",
                    "name": "Serine Proteinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T18",
                    "name": "Serine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}